BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 6158260)

  • 1. Molecular biology and chemistry of the alternative pathway of complement.
    Müller-Eberhard HJ; Schreiber RD
    Adv Immunol; 1980; 29():1-53. PubMed ID: 6158260
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of the alternative complement pathway.
    Fearon DT
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract]   [Full Text] [Related]  

  • 3. Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins.
    Schreiber RD; Pangburn MK; Lesavre PH; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3948-52. PubMed ID: 279011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
    Whaley K; Ward D; Ruddy S
    Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
    Schenkein HA; Ruddy S
    J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Pathol Biol (Paris); 1983 Dec; 31(10):839-46. PubMed ID: 6230588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alternative complement pathway (author's transl)].
    Kazatchkine M; Nydegger U; Fearon DT
    Nouv Presse Med; 1979 Jun; 8(26):2187-94. PubMed ID: 382108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The quest for an intrinsic C3 activating factor in human glomerular disease.
    Roberts JL; Lewis EJ
    Surv Immunol Res; 1982; 1(2):191-8. PubMed ID: 6227068
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alternative complement pathway].
    Jouvin MH; Kazatchkine M
    Sem Hop; 1984 May; 60(19):1371-8. PubMed ID: 6326330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The alternative pathway of complement.
    Pangburn MK; Müller-Eberhard HJ
    Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
    [No Abstract]   [Full Text] [Related]  

  • 12. [Progress in the knowledge of complement. I. Structure, activation and control of the complement system].
    Lesavre P; Leibowitch J
    Nouv Presse Med; 1979 Jun; 8(29):2385-7. PubMed ID: 493022
    [No Abstract]   [Full Text] [Related]  

  • 13. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular aspects of the properdin system.
    Götze O; Medicus RG; Schreiber RD; Müller-Eberhard HJ
    Monogr Allergy; 1977; 12():66-77. PubMed ID: 335221
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
    Harrison RA
    Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
    Whaley K; Thompson RA
    Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The properdin system: composition and function.
    Brade V
    Vox Sang; 1978; 35(1-2):1-9. PubMed ID: 351959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.